The American College of Cardiology (ACC) has announced five Late-Breaking Clinical Trial Sessions, two Late-Breaking Clinical Trial Deep Dive Sessions, and three Featured Clinical Research sessions being presented during its annual scientific session, “ACC with WCC,” or ACC.23/WCC to be held March 4-6 in New Orleans, LA.
February 16, 2023 — The American College of Cardiology (ACC) has announced five Late-Breaking Clinical Trial Sessions, two Late-Breaking Clinical Trial Deep Dive Sessions, and three Featured Clinical Research sessions will be presented during its annual scientific session, “ACC with WCC,” or ACC.23/WCC to be held March 4-6 in New Orleans, La.
“This is practice-changing science,” said Katie Berlacher, MD, MS, FACC, who is serving as ACC.23 Vice Chair, in referencing the late breaking clinical trials and featured clinical research she discussed during the briefing. Berlacher is an Assistant Professor of Medicine at University of Pittsburgh Medical Center, Program Director – Cardiovascular Fellowship, Associate Chief of Education, and part of the UPMC Heart and Vascular Institute. She is currently serving as chair of the ACC Lifelong Learning Oversight Committee.
There will be a total of five late breaking clinical trial sessions, three of which will be joint sessions with the Journal of American College of Cardiology, the Journal of American Medical Association and the New England Journal of Medicine. Berlacher noted there were 146 submissions for late-breaking clinical trials, equally split between from the United States and from international researchers, of which 43 were accepted. All of sessions will be offered on the Hot Topics Channel, one of six provided to expand availability to attendees, both in-person and remote.
The sessions include:
SATURDAY, MARCH 4
Joint American College of Cardiology/Journal of the American College of Cardiology (JACC) Late-Breaking Clinical Trials (Session 402)
9:30 – 10:30 a.m. CT in Main Tent (Great Hall)
CLEAR Outcomes Trial: Bempedoic Acid and Cardiovascular Outcomes in Statin Intolerant Patients at High Cardiovascular Risk
TRILUMINATE Pivotal: A Landmark Randomized Clinical Trial of Transcatheter Tricuspid Valve Edge-to-Edge Repair for Tricuspid Regurgitation
Statins to Prevent the Cardiotoxicity from Anthracyclines: The STOP-CA Trial
Featured Clinical Research I (Session 403)
Noon – 1:15 p.m. CT, Room 257
HALO Trial: Results from a Phase 2, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Baxdrostat in Patients with Uncontrolled Hypertension
Effect of Myocardial Viability, Percutaneous Coronary Intervention and Functional Recovery on Clinical Outcomes in the REVIVED-BCIS2 Randomized Trial
AIMI-HF Trial: Ischemia and Viability Imaging in Heart Failure: The Alternative Imaging Modalities in Ischemic Heart Failure Trial
Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease: A Multimodality Imaging Study (the Yellow III Study)
On-site Computed Tomography-derived Fractional Flow Reserve to Guide the Management of Patients with Stable Coronary Artery Disease: The TARGET Randomized Trial
SUNDAY, MARCH 5
Joint American College of Cardiology/New England Journal of Medicine (NEJM) Late-Breaking Clinical Trials (Session 405)
8 – 9:15 a.m. CT in Main Tent (Great Hall)
Minimally Invasive Versus Conventional Sternotomy for Mitral Valve Repair Surgery: An Expertise Based Multicentre Randomised Controlled Trial (UK Mini Mitral)
Transcatheter Edge-to-edge Repair of Functional Mitral Regurgitation in Heart Failure: Final Five-year Results from the COAPT Trial
Transcatheter Versus Surgical Aortic Valve Replacement in Aortic Stenosis Patients at Low Surgical Risk: 3-year Outcomes from the Evolut Low Risk Trial
BIOVASC: Complete Revascularization Strategies in Patients Presenting with Acute Coronary Syndromes and Multivessel Coronary Disease
RENOVATE-COMPLEX-PCI: Intravascular Imaging-guided Versus Angiography-guided Procedural Optimization in Complex Percutaneous Coronary Intervention
Late-Breaking Clinical Trials III (Session 406)
9:45 – 11 a.m. CT in Main Tent (Great Hall)
Building Electronic Tools to Enhance and Reinforce CArdiovascular REcommendations For Heart Failure (BETTER CARE-HF): A Pragmatic, Cluster-randomized Trial Comparing Two Ambulatory Clinical Decision Support Tools
A Nationwide Randomized Trial of Electronically Delivered Nudges to Increase Influenza Vaccination Uptake: The NUDGE-FLU Trial
Translating Polygenic Risk for Coronary Artery Disease into Clinically Actionable Information Using Causal A.I.
Featured Clinical Research II (Session 407)
12:15 – 1:30 p.m. CT in Main Tent (Great Hall)
RAPID-HF: Atrial Pacing for Heart Failure with Preserved Ejection Fraction: A Randomized Clinical Trial
Comparison of 3-month Versus 12-month Dual Antiplatelet Therapy After Coronary Intervention Using the Contemporary Drug-eluting Stents with Ultrathin Struts and Advanced Polymer Technology: The HOST-IDEA Randomized Clinical Trial
Safety and Efficacy of Transcatheter Edge-to-Edge Mitral Repair in Degenerative Mitral Regurgitation: An Analysis of the STS/ACC TVT Registry
Late-Breaking Clinical Trials Deep Dive I (Session 408)
2 – 3:15 p.m. CT in Main Tent (Great Hall)
Additional insights from key clinical trials presented will be discussed.
Clinical and Investigative Horizons (Session 414)
2 – 3:15 p.m. CT (Room 338)
Prediction of Preeclampsia Using High-Sensitivity Troponin I
Health 360x Registry: Equitable Access to Point of Care Decentralized Clinical Trials
Cardiovascular Disease and Mortality in Black Women Carrying the Amyloidogenic Val122ile Variant
MONDAY, MARCH 6
Joint American College of Cardiology/Journal of the American Medical Association (JAMA) Late-Breaking Clinical Trials (Session 409)
8:30 – 9:45 a.m. CT in Main Tent (Great Hall)
PULSED Field Ablation Treatment in Paroxysmal and Persistent Atrial Fibrillation Patients: Acute and Long-term Outcomes from the PULSED AF Pivotal Trial
Impact of Heart Failure Management Using Thoracic Fluid Monitoring from a Novel Wearable Sensor: Results of the Benefits of Microcor (μCor) in Ambulatory Decompensated Heart Failure (BMAD) Trial
Coordinating Cardiology Clinics Randomized Trial of Interventions to Improve Outcomes (COORDINATE Diabetes): Primary Results
Late-Breaking Clinical Trials V (Session 410)
11 a.m. – 12:15 p.m. CT in Main Tent (Great Hall)
Vigorous Exercise in Individuals with Hypertrophic Cardiomyopathy (HCM): Primary Results of the Prospective, Multinational Lifestyle and Exercise in HCM (LIVE-HCM) Study
Anticoagulation Strategies in Non-critically Ill Hospitalized Covid-19 Patients: Principal Outcomes of the Freedom Covid Anticoagulation Trial
The STELLAR Phase III Trial: A Study of Sotatercept in Combination with Background Therapy For the Treatment of Pulmonary Arterial Hypertension
Efficacy and Safety of the Oral PCSK9 Inhibitor, MK-0616, A Macrocyclic Peptide, in the Treatment of Hypercholesterolemia: A Phase 2b Randomized Placebo-Controlled Clinical Trial
Featured Clinical Research III (Session 411)
12:45 – 2 p.m. CT in La Nouvelle B
Masters@Heart: Lifelong Endurance Exercise and Its Relationship with Coronary Atherosclerosis
Residual Inflammatory Risk in Contemporary Statin Treated Patients: A Collaborative Analyses Of 31,197 Participants in the PROMINENT, REDUCE-IT, and STRENGTH Trials
The LOADSTAR Trial: Comparison Between Targeted Low-Density Lipoprotein Cholesterol Level Based Versus High-Intensity Statin Therapy in Patients with Coronary Artery Disease
CAMEO-DAPA Trial: Evaluation of the Mechanism of Benefit for Dapagliflozin in Heart Failure with Preserved Ejection Fraction: An Invasive Hemodynamic Randomized Trial
Safety and Efficacy of Virtual Care Team Guided Therapeutic Optimization During Hospitalization in Patients with HFrEF: The IMPLEMENT-HF Study
Late-Breaking Clinical Trials Deep Dive II (Session 413)
2:30 – 3:45 p.m. CT in La Nouvelle B
Additional insights from key clinical trials presented will be discussed.
“We really feel that this has been an outstanding year for science at ACC 23 WCC,” said Douglas Drachman, MD, FACC, Chair of the 2023 ACC Scientific Session during his program overview. Drachman is the Director of Education at the Corrigan Minehan Heart Center, and the Teresa G. and Ferdinand F. Martignetti Endowed Chair for Cardiovascular Medicine at Massachusetts General Hospital. He joined ACC staff and ACC.23 Vice Chair Katie Berlacher, MD, MS, FACC to provide a media briefing detailing the broad range of educational and scientific sessions and interactive opportunities scheduled to support cardiologists throughout the 3-day meeting.
For more information:
https://accscientificsession.acc.org
https://accscientificsession.acc.org/en/Plan-Your-Program
Related content:
American College of Cardiology Announces “ACC.23 Together with WCC” Program Highlights
August 08, 2024 
